Co-Amilofruse 10/80mg Tablets
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Co-Amilofruse 10/80mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 10mg of Amiloride Hydrochloride (dihydrate) and 80mg of Furosemide.
For a full list of excipients, see section 6. 1.
3 PHARMACEUTICAL FORM
Tablets for oral use.
Pale orange circular, flat faced beveled edge tablets debossed with ARD | 80 on one side and plain on the other side.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Co-Amilofruse is indicated where a prompt diuresis is required especially in conditions where potassium conservation is important: congestive cardiac failure, nephrosis, fluid retention due to corticosteroid or oestrogen therapy and ascites associated with cirrhosis.
4.2 Posology and method of administration
The starting dose is usually 5/40mg, subsequent dosage being adjusted to suit the needs of the patient.
Adults:
One to two tablets to be taken in the morning.
Children:
Not indicated for children.
Elderly:
The dosage should be adjusted according to diuretic response. Serum electrolytes and urea should be carefully monitored.
4.3 Contraindications
Patients with hypovolaemia or dehydration (with or without accompanying hypotension). Patients with an impaired renal function and a creatinine clearance below 30ml/min per 1.73 m2 body surface area, anuria or renal failure with anuria not responding to furosemide, renal failure as a result of poisoning by nephrotoxic or hepatotoxic agents or renal failure associated with hepatic coma, severe hypokalaemia, severe hyponatraemia, hyperkalaemia (serum potassium > 5.3 mmol/llitre), addison's disease, precomatose states associated with cirrhosis, concomitant potassium supplements or potassium sparing diuretics, electrolyte imbalance and breast feeding women.
Co-Amilofruse is contraindicated in children and adolescents less than 18 years of age, as safety in this age group has not been established.
Hypersensitivity to furosemide, amiloride, sulphonamides or sulphonamide derivatives, or any of the excipients of the product.
4.4 Special warnings and precautions for use
Co-Amilofruse should be discontinued before a glucose tolerance test. Particularly careful monitoring is necessary in:
- patients with hypotension.
- patients who are at risk from a pronounced fall in blood pressure.
- patients where latent diabetes may become manifest or the insulin requirements of diabetic patients may increase.
- patients with gout.
- patients with hepatic cirrhosis together with impaired renal function.
- patients with hypoproteinaemia, e.g. associated with nephrotic syndrome (the effect of furosemide may be weakened and its ototoxicity potentiated). Cautious dose titration is required.
Caution should be observed in patients liable to electrolyte deficiency. Regular monitoring of serum sodium, potassium, creatinine and glucose is generally recommended during therapy; particularly close monitoring is required in patients at high risk of developing electrolyte imbalances or in case of significant additional fluid loss. Hypovolaemia or dehydration as well as any significant electrolyte and acid-base disturbances must be corrected. This may require temporary discontinuation of Co-Amilofruse.
Frequent checks of the serum potassium level are necessary in patients with
2
impaired renal function and a creatinine clearance below 60ml/min per 1.73m body surface area as well as in cases where Co-Amilofruse is taken in combination with certain other drugs which may lead to an increase in potassium levels.
In patients who are at high risk for radiocontrast nephropathy, furosemide is not recommended to be used for diuresis as part of the preventative measures against radiocontrast-induced nephropathy.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Urinary output must be secured. Patients with partial obstruction of urinary outflow, for example patients with prostatic hypertrophy or impairment of micturition have an increased risk of developing acute urinary retention and require careful monitoring.
Where indicated, steps should be taken to correct hypotension or hypovolaemia before commencing therapy.
Co-Amilofruse should be used with caution in elderly or those with potential obstruction of the urinary tract or disorders rendering electrolyte balance precarious.
Concomitant use with risperidone
In risperidone placebo-controlled trials in elderly patients with dementia, a higher incidence of mortality was observed in patients treated with furosemide plus risperidone (7.3%; mean age 89 years, range 75-97 years) when compared to patients treated with risperidone alone (3.1%; mean age 84 years, range 7096 years) or furosemide alone (4.1%; mean age 80 years, range 67-90 years). Concomitant use of risperidone with other diuretics (mainly thiazide diuretics used in low dose) was not associated with similar findings.
No pathophysiological mechanism has been identified to explain this finding, and no consistent pattern for cause of death observed. Nevertheless, caution should be exercised and the risks and benefits of this combination or cotreatment with other potent diuretics should be considered prior to the decision to use. There was no increased incidence of mortality among patients taking other diuretics as concomitant treatment with risperidone. Irrespective of treatment, dehydration was an overall risk factor for mortality and should therefore be avoided in elderly patients with dementia (see section 4.3 Contraindications).
The possibility exists of exacerbation or activation of systemic lupus erythematosus.
4.5 Interaction with other medicinal products and other forms of interaction
The dosage of concurrently administered cardiac glycosides, diuretics, antihypertensive agents, or other drugs with blood-pressure-lowering potential may require adjustment as a more pronounced fall in blood pressure must be anticipated if given concomitantly with Co-Amilofruse. A marked fall in blood pressure and deterioration in renal function may be seen when ACE inhibitors or angiotensin II receptor antagonists are added to furosemide therapy, or their dose level increased. The dose of Co-Amilofruse should be reduced for at least three days, or the drug stopped, before initiating the ACE inhibitor or angiotensin II receptor antagonist or increasing their dose.
When amiloride is taken in combination with potassium salts, with drugs which reduce potassium excretion, with nonsteroidal anti-inflammatory drugs or with ACE inhibitors, an increase in serum potassium concentration and hyperkalaemia may occur.
The toxic effects of nephrotoxic drugs may be increased by concomitant administration of potent diuretics such as furosemide.
Oral Co-Amilofruse and sucralfate must not be taken within 2 hours of each other because sucralfate decreases the absorption of furosemide from the intestine and so reduces its effect.
In common with other diuretics, serum lithium levels may be increased when lithium is given concomitantly with Co-Amilofruse, resulting in increased lithium toxicity, including increased risk of cardiotoxic and neurotoxic effects of lithium. Therefore, it is recommended that lithium levels are carefully monitored and where necessary the lithium dosage is adjusted in patients receiving this combination.
Risperidone: Caution should be exercised and the risks and benefits of the combination or co-treatment with furosemide or with other potent diuretics should be considered prior to the decision to use. See section 4.4 Special warnings and precautions for use regarding increased mortality in elderly patients with dementia concomitantly receiving risperidone.
Certain non-steroidal anti-inflammatory agents (e.g. indometacin, acetylsalicylic acid) may attenuate the action of Co-Amilofruse and may cause acute renal failure in cases of pre-existing hypovolaemia or dehydration. Salicylic toxicity may be increased by furosemide. Co-Amilofruse may sometimes attenuate the effects of other drugs (e.g. the effects of anti-diabetics and of pressor amines) and sometimes potentiate them (e.g. the effects of salicylates, theophylline and curare-type muscle relaxants).
Furosemide may potentiate the ototoxicity of aminoglycosides and other ototoxic drugs. Since this may lead to irreversible damage, these drugs must only be used with Co-Amilofruse if there are compelling medical reasons.
There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly. In addition, nephrotoxicity of cisplatin may be enhanced if furosemide is not given in low doses (e.g. 40 mg in patients with normal renal function) and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment.
Amiloride may cause raised blood digoxin levels. Some electrolyte disturbances (e.g. hypokalaemia, hypomagnesaemia) may increase the toxicity of certain other drugs (e.g. digitalis preparations and drugs inducing QT interval prolongation syndrome).
Attenuation of the effect of Co-Amilofruse may occur following concurrent administration of phenytoin.
Concomitant administration of carbamazepine or aminoglutethimide may increase the risk of hyponatraemia.
Corticosteroids administered concurrently may cause sodium retention.
Corticosteroids, carbenoxolone, liquorice, B2 sympathomimetics in large amounts, and prolonged use of laxatives, reboxetine and amphotericin may increase the risk of developing hypokalaemia.
Probenecid, methotrexate and other drugs which, like furosemide, undergo significant renal tubular secretion may reduce the effect of Co-Amilofruse. Conversely, furosemide may decrease renal elimination of these drugs. In case of high-dose treatment (in particular, of both furosemide and the other drugs), this may lead to increased serum levels and an increased risk of adverse effects due to furosemide or the concomitant medication.
Impairment of renal function may develop in patients receiving concurrent treatment with furosemide and high doses of certain cephalosporins
Concomitant use of ciclosporin and furosemide is associated with increased risk of gouty arthritis.
4.6 Pregnancy and lactation
Pregnancy:
Results of animal work, in general, show no hazardous effect of furosemide in pregnancy. There is clinical evidence of safety of the drug in the third trimester of human pregnancy; however, furosemide crosses the placental barrier. It must not be given during pregnancy unless there are compelling medical reasons. Treatment during pregnancy requires monitoring of foetal growth.
The safety of Amiloride Hydrochloride has not been established and is therefore not recommended for use during pregnancy.
Lactation:
Furosemide passes into breast milk and may inhibit lactation. It is not known whether Amiloride Hydrochloride is excreted in breast milk. Breastfeeding must be avoided during treatment with Co-Amilofruse.
4.7 Effects on ability to drive and use machines
None known
4.8 Undesirable effects
Adverse effects have been ranked under headings of frequency using the following convention: very common (>1/10); common (>1/100; <1/10); uncommon (>1/1,000;< 1/100); rare (>1/10,000;<1/1,000); very rare (<1/10,000); frequency not known (cannot be estimated from the available data).
Frequencies for the following adverse reactions are not known (cannot be estimated form available data):
Co-Amilofruse Tablets are generally well tolerated.
Blood and lymphatic system disorders Eosinophilia is rare.
Occasionally, thrombocytopenia may occur. In rare cases, leucopenia and, in isolated cases, agranulocytosis, aplastic anaemia or haemolytic anaemia may develop.
Bone marrow depression has been reported as a rare complication and necessitates withdrawal of treatment.
Severe fluid depletion may lead to haemoconcentration with a tendency for thromboses to develop.
Nervous system disorders
Rarely, paraesthesiae or hepatic encephalopathy in patients with hepatocellular insufficiency may occur (see section 4.3).
Metabolism and nutrition disorders
Serum calcium levels may be reduced; in very rare cases tetany has been observed.
Serum cholesterol and triglyceride levels may rise during furosemide treatment. During long term therapy they will usually return to normal within six months.
Glucose tolerance may decrease with furosemide. In patients with diabetes mellitus this may lead to a deterioration of metabolic control; latent diabetes mellitus may become manifest.
As with other diuretics, electrolytes and water balance may be disturbed as a result of diuresis after prolonged therapy. Furosemide leads to increased excretion of sodium and chloride and consequently water. In addition excretion of other electrolytes (in particular potassium, calcium and magnesium) is increased. However, as treatment is continued, the serum potassium concentration may increase due to the later onset of action of amiloride, especially in patients with impaired renal function. Symptomatic electrolyte disturbances and metabolic alkalosis may develop in the form of a gradually increasing electrolyte deficit or, e.g. where higher furosemide doses are administered to patients with normal renal function, acute severe electrolyte losses, although amiloride may contribute to the development or aggravation of metabolic acidosis. Warning signs of electrolyte disturbances include increased thirst, headache, hypotension, confusion, muscle cramps, tetany, muscle weakness, disorders of cardiac rhythm and gastrointestinal symptoms. Disturbances of electrolyte balance, particularly if pronounced, must be corrected. Pre-existing metabolic alkalosis (e.g. in decompensated cirrhosis of the liver) may be aggravated by furosemide treatment. Pseudo-Bartter syndrome may occur in the context of misuse and/or long-term use of furosemide.
The diuretic action of furosemide may lead to or contribute to hypovolaemia and dehydration, especially in elderly patients.
As with other diuretics, treatment with furosemide may lead to transitory increases in blood creatinine and urea levels. Serum levels of uric acid may increase and attacks of gout may occur.
Ear and labyrinth disorders
Hearing disorders and tinnitus, although usually transitory, may occur in rare cases, particularly in patients with renal failure, hypoproteinaemia (e.g. in nephritic syndrome) and/or when intravenous furosemide has been given too rapidly. Cases of deafness, sometimes irreversible, have been reported after administration of furosemide.
Vascular disorders
Furosemide may cause a reduction in blood pressure which, if pronounced may cause signs and symptoms such as impairment of concentration and reactions, light-headedness, sensations of pressure in the head, headache, dizziness, drowsiness, weakness, disorders of vision, dry mouth, orthostatic intolerance.
Hepato-biliary disorders
In isolated cases, intrahepatic cholestasis, an increase in liver transaminases or acute pancreatitis may develop.
Skin and subcutaneous tissue disorders
The incidence of allergic reactions, such as skin rashes, photosensitivity, vasculitis, fever, interstitial nephritis, or shock is very low, but when these occur treatment should be withdrawn. Skin and mucous membrane reactions may occasionally occur, e.g. itching, urticaria, other rashes or bullous lesions, erythema multiforme, bullous pemphigoid, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, purpura AGEP (acute generalized exanthematous pustulosis) and DRESS (Drug rash with eosinophilia and systemic symptoms).
Psychiatric disordersRare complications may include minor psychiatric disturbances.
Renal and urinary disorders
Increased production of urine may provoke or aggravate complaints in patients with an obstruction of urinary outflow. Thus, acute retention of urine with possible secondary complications may occur. for example, in patients with bladder-emptying disorders, prostatic hyperplasia or narrowing of the urethra. Nephrocalcinosis / Nephrolithiasis has been reported in premature infants.
Reproductive system and breast disorders
If furosemide is administered to premature infants during the first weeks of life, it may increase the risk of persistence of patent ductus arteriosus.
Immune system disorders
Severe anaphylactic or anaphylactoid reactions (e.g. with shock) occur rarely.
Unknown: exacerbation or activation of systemic lupus erythematosus.
Gastrointestinal disordersMinor side effects are nausea, vomiting, malaise, gastric upset, diarrhoea and constipation may occur but are not usually severe enough to necessitating withdrawal of the treatment.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
4.9 Overdose
Treatment should be aimed at reversing dehydration and correcting electrolyte imbalance, particularly hyperkalaemia. If hyperkalaemia is seen, appropriate measures to reduce serum potassium must be instituted. Emesis should be induced or gastric lavage performed. Treatment is symptomatic and supportive.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherpeutic Group: High-ceiling diuretics and potassium-sparing agents
ATC code: C03CA01-Furosemide, C03DB01-Amiloride.
Furosemide is a potent loop diuretic which acts primarily inhibiting effects on electrolyte reabsorption in the thick ascending loop of Henle. Excretion of sodium, potassium and chloride ions is increased and water excretion enhanced.
Amiloride hydrochloride is a mild diuretic, which appears to act mainly on the distal renal tubules. It does not appear to act by inhibition of aldosterone and does not inhibit carbonic anhydrase. It increases the excretion of sodium and chloride and reduces the excretion of potassium. Amiloride adds to the natriuretic but diminishes the kaliuretic effects of other diuretics.
A combination of Furosemide and Amiloride is a diuretic which reduces the potassium loss of furosemide alone while avoiding the possible gastrointestinal disturbances of potassium supplements.
5.2 Pharmacokinetic properties
Furosemide: Approximately 65% of the dose is absorbed after oral administration. It has a biphasic half-life in the plasma with a terminal elimination phase that has been estimated to range up to one and half-hours. It is up to 99% bound to plasma proteins, and is mainly excreted in the urine, largely unchanged, but also in the form of the glucuronide and free amine metabolites. Variable amounts are also excreted in bile, non-renal elimination being considerably increased in renal failure. Furosemide crosses the placental barrier and is excreted in milk.
Amiloride: Approximately 50% of the dose is absorbed after oral administration and peak serum concentrations are achieved by three to four hours. Amiloride is not bound to plasma proteins. It is excreted unchanged in the urine, and animal studies have shown little evidence of any biliary excretion. Amiloride has been estimated to have a serum half-life of about six hours.
Pharmacokinetic studies have been completed on Frumil 40 mg/5 mg Tablets/Lasoride.
FUROSEMIDE:
Cp MAX = 1/14 pg/ml SD = 0.67
Tmax = 3.0 hours
AUC = 3.17pg/ml hr SD = ± 1.25
AMILORIDE:
Cp MAX = 13.42 ng/ml SD = 5.74
Tmax = 4.0 hours
AUC = 154 ng/ml hr SD = ± 65.2
5.3 Preclinical safety data
There are no pre-clinical data of any relevance to the prescriber, which are additional to those already included in other sections.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose monohydrate Microcrystalline Cellulose Sunset Yellow FCF Lake (E110) Povidone K30 Sodium Starch Glycollate Magnesium Stearate
6.2 Incompatibilities
None known.
6.3 Shelf life
36 months
6.4 Special precautions for storage
Do not store above 25°C.Store in the original package. Keep the containers tightly closed.
6.5 Nature and contents of container
Opaque white blister packs manufactured from UP VC and aluminium foil containing 28, 30, 56, or 60 tablets.
Polypropylene or polyethylene containers with a lid containing 500 tablets.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
None
7 MARKETING AUTHORISATION HOLDER
Aurobindo Pharma Limited Ares Block
Odyssey Business Park West End Road South Ruislip
HA46QD United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 20532/0085
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
19/03/2009
10 DATE OF REVISION OF THE TEXT
27/11/2015